🇺🇸 FDA
Patent

US 11369692

Materials and methods for treatment of Duchenne Muscular Dystrophy

granted A61KA61K35/28A61K35/34

Quick answer

US patent 11369692 (Materials and methods for treatment of Duchenne Muscular Dystrophy) held by Vertex Pharmaceuticals Incorporated expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K35/28, A61K35/34, A61K38/465, A61K48/005